Endometrial Transitional Cell Carcinoma
5 clinical trials · Condition
◉ Watch Endometrial Transitional Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013) | National Cancer Institute (NCI) | 2017-01-30 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01642082) | Gynecologic Oncology Group | 2012-09-01 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01225887) | Gynecologic Oncology Group | 2011-10-01 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998) | National Cancer Institute (NCI) | 2011-09-20 |
Track Endometrial Transitional Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.